warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
TANGO-2
Brief Description  
This study is comparing standard of care treatments for patients with CRE (Carbapenem-Resistant Enterobacteriaceae). Eligible patients will be randomized 2:1 to either the investigational antibiotic Carbavance or standard of care. Carbavance is a combination medication consisting of meropenem (an approved antibiotic) and RPX7009. Patients will be treated up to 14 days and followed up to 2 weeks after treatment completion.
Who may be Eligible  
Adults patients with know CRE infection; not pregnant or breastfeeding; agree to not become pregnant or father a child up to 30 days after study medication; agree to protocol defined birth control; normal maintenance labs as defined by protocol; not allergic to study medications; no co-morbid condition that will interfere with the study as defined by protocol; life expectancy greater than 72 hours; know or suspected endocarditis, meningitis, or osteomyelitis;
Start Date  
03/01/2016
IRB Number  
03-16-01A
Principal Investigator  
Polk, Christopher
Contact Name  
Jessica

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Email:  Jessica.kearney-bryan@carolinashealhcare.org
Address:1350 S. Kings Drive, 3rd floor ID Clinic Charlotte, NC 28207
Close